Form 8-K Nuvation Bio Inc. For: Nov 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street falls as oil rebounds, Middle East tensions simmer
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Nuvation Bio discontinues NUV-1511 drug development program
November 26, 2025 8:37 AM ESTNuvation Bio Inc. (NYSE: NUVB) announced November 26 that it will discontinue development of NUV-1511, the first compound in its drug-drug conjugate program. The company cited lack of sufficiently consistent efficacy across patient cohorts as the reason for the decision.
While NUV-1511 was... More
